Affimed Stock Forecast, Price & News

-0.05 (-0.73 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume695,116 shs
Average Volume2.41 million shs
Market Capitalization$671.30 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Affimed logo

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.90 out of 5 stars

Medical Sector

398th out of 2,214 stocks

Pharmaceutical Preparations Industry

203rd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Affimed (NASDAQ:AFMD) Frequently Asked Questions

Is Affimed a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed
or view top-rated stocks.

What stocks does MarketBeat like better than Affimed?

Wall Street analysts have given Affimed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Affimed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Affimed?

Affimed saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 4,080,000 shares, a decrease of 24.2% from the June 15th total of 5,380,000 shares. Based on an average daily volume of 2,000,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.7% of the shares of the company are sold short.
View Affimed's Short Interest

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Affimed

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) issued its quarterly earnings data on Wednesday, June, 30th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.11. Affimed had a negative net margin of 88.48% and a negative trailing twelve-month return on equity of 37.87%.
View Affimed's earnings history

How has Affimed's stock been impacted by COVID-19 (Coronavirus)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AFMD shares have increased by 275.3% and is now trading at $6.83.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AFMD?

5 analysts have issued 12-month price objectives for Affimed's stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate Affimed's stock price to reach $13.80 in the next year. This suggests a possible upside of 102.0% from the stock's current price.
View analysts' price targets for Affimed
or view top-rated stocks among Wall Street analysts.

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 60, Pay $871.35k)
  • Mr. Angus W. Smith, Chief Financial Officer (Age 39, Pay $558.82k)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 57, Pay $685.14k)
  • Dr. Arndt J. G. Schottelius, Chief Scientific Officer (Age 55, Pay $625.34k)
  • Dr. Andreas Harstrick M.D., Chief Medical Officer (Age 60, Pay $487.24k)
  • Prof. Melvyn Little, Founder & Consultant
  • Ms. Denise Mueller, Chief Bus. Officer & Pres of Affimed Inc. and Member of Management Board
  • Mr. Michael Wolf, Head of Fin. & Admin. (Age 54)
  • Mr. Alexander Fudukidis, Head of Investor Relations
  • Dr. Uwe Reusch, Head of Cell Culture

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of retail and institutional investors. Top institutional investors include Lindbrook Capital LLC (0.01%).

Which institutional investors are buying Affimed stock?

AFMD stock was purchased by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $6.83.

How much money does Affimed make?

Affimed has a market capitalization of $671.30 million and generates $32.39 million in revenue each year. The biopharmaceutical company earns $-47,250,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Affimed have?

Affimed employs 153 workers across the globe.

What is Affimed's official website?

The official website for Affimed is

Where are Affimed's headquarters?

Affimed is headquartered at TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.